Dermatology - European Medical Journal

This site is intended for healthcare professionals

Continue

Dermatology

Filter
8 Mins
15 Dec 2020

The Other Side of the Moon: A Clinical Dialogue on the IL-23 Pathway

Prof Reich began by highlighting how insights into the pathophysiology of psoriasis have led to the development and expansion of cytokine-targeted…
Derm 8.1 feature image
6 Mins
15 Dec 2020

Latest Highlights on Biologic Treatments for Psoriasis and Psoriatic Arthritis from EADV 2020

The VOYAGE 1 trial1 was a placebo- and active-controlled Phase III study to evaluate long-term efficacy and safety of the IL-23p19 inhibitor guselkumab…
Derm 8.1 feature image
8 Mins
15 Dec 2020

Bimekizumab Efficacy and Safety in Patients with Moderate-to-Severe Plaque Psoriasis

Psoriasis is a Th17-driven disease, with both IL-17A and IL-17F playing a pivotal role in its pathogenesis.2,3 BKZ is a monoclonal IgG1 antibody…
6 Mins
23 Jun 2020

Chlormethine Gel for Mycosis Fungoides T-cell Lymphoma: Recent Real-World Data

An enhanced understanding of real-world CL Gel usage could help improve the management of patients with MF-CTCL…
9 Mins
14 May 2020

Highlights of the European Organisation for Research and Treatment of Cancer-Cutaneous Lymphoma Task Force (EORTC-CLTF) Annual Congress 2019 (Athens, Sept 26-28): Experiences with Chlormethine Gel in Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)

MF-CTCL is a rare type of cutaneous non-Hodgkin’s lymphoma where uncontrolled growth of the pathological skin-homing T-lymphocytes results first in skin…
9 Mins
28 Feb 2020

Biologics in Moderate-to-Severe Psoriasis: Discover the Road to Long-term Control

Advances in the treatment of moderate-to-severe psoriasis have accelerated considerably in the last 30 years. Prof Piaserico provided an overview of the…
8 Mins
28 Feb 2020

Tildrakizumab in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analyses on Efficacy, Time to Relapse, Long-Term Safety in Elderly Population and Predictability From The reSURFACE 1 and reSURFACE 2 Phase III Clinical Trials

Psoriasis is a chronic, relapsing inflammatory skin disease, characterised in most cases by sharply demarcated, erythematous, pruritic plaques covered…
4 Mins
28 Feb 2020

Long-Term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis through 3 Years (148 Weeks) from reSURFACE 1 and reSURFACE 2 Phase III Trials

IL-23 plays a key regulatory role in the pathogenesis of plaque psoriasis and medications targeting IL-23 have been shown to be effective for people with…
We’ve noticed you’re accessing
from North/South America.